Aripiprazole versus risperidone in the treatment of children and adolescents with tic disorders

Aripiprazole versus risperidone in the treatment of children and adolescents with tic disorders, a double blind randomized controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201301053930N17

Enrollment

Registered

2013-02-08

Start date

2012-08-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tic disorder. Tic disorders

Interventions

Intervention 1: Risperidone up to 3 mg/day. Intervention 2: Aripiprazole up to 10 mg/day.

Treatment - Drugs

Risperidone up to 3 mg/day

Aripiprazole up to 10 mg/day

Eligibility

Sex/Gender

All

Age

5 Years to 19 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: children and adolescents aged 6 to 18 years; total score of YGTS more than 21. Exclusion criteria: Marked general medical condition; hypersensitivity to the medications.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Yale global tic severity scale. Timepoint: Every 4 weeks. Method of measurement: interview.	—

Secondary

Measure	Time frame
Adverse effects checklist. Timepoint: every 4 weeks. Method of measurement: checklist.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026